Epizyme, Inc
EPZM
EPZM was delisted on the 11th of August, 2022.
95 hedge funds and large institutions have $823M invested in Epizyme, Inc in 2017 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 30 increasing their positions, 30 reducing their positions, and 8 closing their positions.
1,030% more call options, than puts
Call options by funds: $1.51M | Put options by funds: $134K
75% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 8
40% more capital invested
Capital invested by funds: $589M → $823M (+$234M)
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
1% more funds holding
Funds holding: 94 → 95 (+1)
0% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 30
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$42.8M |
| 2 |
PAI
Palo Alto Investors
Palo Alto,
California
|
+$23.4M |
| 3 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
+$6.89M |
| 4 |
CC
Casdin Capital
New York
|
+$2.8M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.85M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MAM
MPM Asset Management
Boston,
Massachusetts
|
-$20.9M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$15.7M |
| 3 |
VOYA Investment Management
Atlanta,
Georgia
|
-$4.97M |
| 4 |
DM
Deerfield Management
New York
|
-$2.5M |
| 5 |
QF
QVT Financial
New York
|
-$2.33M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TC
101
TFS Capital
West Chester,
Pennsylvania
| – | -$125K | -10,330 | Closed |
|
102
US Bancorp
Minneapolis,
Minnesota
| – | -$24K | -2,000 | Closed |
|
|
TRCT
103
Tower Research Capital (TRC)
New York
| – | -$6K | -490 | Closed |
|
EPZM Hedge Fund Activity: Q1 2017 in Review
95 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Epizyme, Inc (EPZM) for Q1 2017, worth a combined $823M — up 40% from $589M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new EPZM positions and 8 closed out — a net gain of 6 holders — while 30 added to existing stakes and 30 trimmed.
The largest buyer was BlackRock, adding an estimated $42.8M. The largest seller was MPM Asset Management, exiting entirely with an estimated $20.9M sold.
- 95 institutional investors held Epizyme, Inc (EPZM) as of Q1 2017, up from 94 in Q4 2016.
- Funds reported $823M of Epizyme, Inc stock for Q1 2017, up 40% quarter-over-quarter.
- 14 funds opened new Epizyme, Inc positions in Q1 2017 and 8 closed out, a net change of +6 holders.
- The largest Epizyme, Inc buyer in Q1 2017 was BlackRock, an estimated $42.8M added.
- The largest Epizyme, Inc seller in Q1 2017 was MPM Asset Management, an estimated $20.9M sold.
Based on aggregated 13F filings for Q1 2017.